Introduction {#Sec1}
============

Bisphosphonates (BPs) are well-known substances with very efficient antiresorptive properties \[[@CR1], [@CR2]\]. Therefore, BPs have important effects on bone turnover and are widely used to treat a variety of diseases such as osteoporosis, bone metastasis, hypercalcemia of malignancy, Paget's disease, osteogenesis imperfecta or fibrous dysplasia of bone \[[@CR3], [@CR4]\]. Their beneficial actions not only aid in the achievement of better bone mineral density also are useful in the improvement in bone microarchitecture, strength and, consequently, its quality \[[@CR5], [@CR6]\]. BPs regulate osteoblastic functions such as proliferation and differentiation, prevent osteoblast apoptosis, modulate osteoblastic production of extracellular matrix proteins and regulate osteoblastic expression and secretion of various growth factors and cytokines \[[@CR7]--[@CR9]\]. Recent studies indicate that the most promising roles for the BPs are the prevention of bone collapse following osteonecrosis and the enhancement of implant fixation. Such combination therapies that have both bone antiresorptive and anabolic agents appear to be of great promise for other further orthopedic applications \[[@CR3]\].

Modern generation of cementing techniques has really affected the survivorship of the use of orthopedic implants. Despite the optimization of cement preparation and proper initial cementing technique, the biomechanical properties of the bone cement used seem to be very important in preventing the further aseptic loosening of the implant \[[@CR10]\]. Nowadays, PMMA-based bone cement (methyl polymethacrylate) seems to be most effective in total joint replacements implants. The first use of PMMA in a hip joint alloplasty was in the early 1960s when Charnley anchored the hip joint endoprosthesis inside the femur. Surgical cement, being a polymer composite, sets using an elemental bonding prosthesis with bone, and thus, it is required to be highly biocompatible and biotolerant. Many kinds of cements, either as pure polymer or with admixtures of different substances, are used. Application of fillers is of great significance to the mechanical properties of the PMMA. Specificity of the working conditions forces the necessity of transition of extremely complex loading resulting from human motor activity. Working environment of the bone cement is highly aggressive, which dramatically increases the aging rate and causes higher enucleating of the cement, weakening the bone--cement--implant system. This phenomenon can lead to endoprosthesis loosening and to the necessity of a reimplantation procedure \[[@CR11]\]. The most important mechanical properties of PMMA cement are tensile, compressive, shear and fracture toughness. The variation in these properties is related to differences in composition, mixing methods, aging, temperature and viscosity during application. Such biomechanical parameters are mostly responsible for dynamic and static loads. PMMA is a very specific material of high modulus and low ductility \[[@CR10]\]. Therefore, a high degree of stiffness of the bone cement is very important. The lack of this stiffness is responsible for the creep deformation, which is the tendency of a solid material to move slowly or deform permanently over the time under the influence of stresses \[[@CR12]\]. However, creep deformation can be influenced by such factors as porosity, cement composition or molecular weight \[[@CR13]\].

The goal of the presented study was to assess whether the enrichment of bone cement with pamidronate has changed its biomechanical properties. We compared the biomechanical parameters of clean bone cement and BP-enriched bone cement which were both used in our former rat model.

Our previous animal studies demonstrated that local treatment with BPs can affect the level of bone turnover markers in blood serum \[[@CR14]\]. We also proved that there are significant changes in the microarchitectural bone structure during the local use of pamidronate. Therefore, BP-enriched bone cement used in rat models had a positive effect on bone formation \[[@CR15]\].

Materials and methods {#Sec2}
=====================

Reagents {#Sec3}
--------

Bisphosphonate, pamidronate (Pamifos 60), was purchased from Vipharm (Warsaw, Poland). Bone cement was purchased from CMW 1, DePuy International Ltd, England. Research was performed on probes of BP-enriched bone cement where 40 g of cement was mixed with 60 mg pamidronate by using a vacuum mixer. Then, it was compared with probes of clean bone cement.

Biomechanical testing {#Sec4}
---------------------

Biomechanical properties of the material are defined by two basic terms: stress and strain, which are caused by the influence of external force applied to a solid. In the investigatory process of the bone's biomechanical parameters, the compressive test and the three-point flexural tests were used. During the three-point flexural investigation, the sample was supported at both ends and loaded in the middle, resulting in a flexure. After a specific range of flexure, the sample was fractured.

The three-point flexural test of bone cement and bisphosphonate-enriched bone cement was performed using a computerized testing machine, Instron 5965L1684 (Fig. [1](#Fig1){ref-type="fig"}). Samples in the form of cylinders of diameter *d*~0~ = 12.0 mm were placed in the holder (length of support span *L* = 2.0 cm) and then exposed to a cross-load with 2 mm/min speed which caused the fracture, according to the method \[[@CR16], [@CR17]\]. Based on mechanical characteristics obtained during three-point flexural test, the load (*F*) and stress (M) at the point of maximal load which causes cracking, and deflection (*l*) and strain (*δ*) of the sample to this point were determined. Treating the sample as a rod of radius 6.0 mm, transverse Young's modulus (*E*~τ~):$$\documentclass[12pt]{minimal}
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The maximum energy (*W*) absorbed by the sample before the fracture occurred was also determined. This energy is defined as the area under the curve of mechanical characteristics to the point of the maximal load. From load--deflection characteristics, the stiffness (*H*~τ~) was determined as the slope of rectilinear region.

Compression tests were performed on samples in the form of a cylinder with a diameter of 12.0 mm and height 10.0 mm using the same measuring device (Instron 5965L1684). Longitudinal Young's modulus (*E*~p~) and stiffness (*H*~p~) of the samples at maximum load 5 kN were determined. In this regard, none of the samples had been destroyed.

Density of the samples was determined by using gas densitometer ULTRAPYC 1200e.

FTIR measurements {#Sec5}
-----------------

Fourier-transform infrared spectra were recorded with Nicolet 6700 FTIR spectrometer from Thermo Scientific Company. To register the FTIR spectrum of each sample, 1 mg of powder of bone cement and 1 mg of the powder of bisphosphonate-enriched bone cement were mixed with 200 mg KBr and compressed into a pellet for FTIR analysis. The spectra were received in the range of 400--3,000 cm^−1^ with a frequency resolution of 4 cm^−1^ in the transmission mode. For each sample, 16 scans were accumulated, Fourier-transformed and averaged. Background spectra were recorded before each sample to exclude the impact of external factors.

Statistical analysis {#Sec6}
--------------------

Statistical analyses were performed using one-way analyses of variance (ANOVA). Post-hoc comparison of means was carried out with Tukey's test for multiple comparisons, when appropriate. For this case, all data are shown as the mean ± SEM. For cases with rejected hypothesis of normal distribution or homogeneity of variance, nonparametric ANOVA rank and Kruskal--Wallis multiple comparisons were used. The data are shown as the median with the first and third quartiles. The data were considered statistically significant at confidence limit of *p* \< 0.05. All statistical calculations were performed using 10.0 STATISTICA software (StatSoft, Poland).

Results {#Sec7}
=======

A typical load--deflection curve for bone cement samples is shown at Fig. [2](#Fig2){ref-type="fig"} and for bisphosphonate-enriched bone cement at Fig. [3](#Fig3){ref-type="fig"}. The value of the load (*F*) was registered on the ordinate axis and the deflection (*l*) of the samples (the movement of the head shift) on the abscissa axis. Fig. 2Load--deflection curve for bone cement obtained during three-point flexural testFig. 3Load--deflection curve for bisphosphonate-enriched bone cement obtained during three-point flexural test

Biomechanical parameters were determined based on the characteristics from the three-point flexural test and the compressive test, and the densities (*ρ*) of the bone cement and bisphosphonate-enriched bone cement samples are shown in Table [1](#Tab1){ref-type="table"}. The table shows the mean values, standard deviation and the statistical significance level between bisphosphonate-enriched bone cement samples and pure bone cement samples. Table 1Biomechanical parameters and density of bone cement and bisphosphonate-enriched bone cementParameterBone cement ± SDBisphosphonate-enriched bone cement ± SD*pF* (N)3,306 ± 2393,324 ± 4370.7232*M* (MPa)95.00 ± 6.8692.69 ± 12.570.7232*l* (mm)1.21 ± 0.091.24 ± 0.170.7363*δ* (%)22.0 ± 2.024.0 ± 3.0\>0.8*E* ~τ~ (MPa)433.78 ± 1.71415.03 ± 12.040.0087\**H* ~τ~ (N/mm)2,773.3 ± 9.82,607.3 ± 88.40.0132\**W* (J)2.07 ± 0.292.13 ± 0.51\>0.8*E* ~p~ (MPa)1,240.0 ± 7.01,229.0 ± 10.00.1194*H* ~p~ (kN/mm)14.23 ± 0.0614.10 ± 0.110.0656*ρ* (kg/m^3^)1,248 ± 101,250 ± 100.7599*F*---load, *M*---stress, *l*---deflection, *δ*---strain, *E* ~τ~---transverse Young's modulus (three-point flexural test), *H* ~τ~---stiffness from the three-point flexural test, *W*---energy stored in the sample before fracture, *E* ~p~---longitudinal Young's modulus (compressive test), *H* ~p~---stiffness from compressive test, *ρ*---density\* Significance value

The examinations conducted show that samples were destroyed in the elastic region. There were no significant differences of maximal load, but in the case of bisphosphonate-enriched bone cement, we observed an increase in strain (4.5 %) in comparison with pure bone cement. Stiffness of the bisphosphonate-enriched bone cement samples was 5 % less during three-point flexural test (*p* = 0.0087) and about 1 % during the compressive test (*p* = 0.06). Significant changes were observed in the values of transverse Young's modulus, which was about 4 % less in bisphosphonate-enriched bone cement samples.

There were no significant differences in the values of the stress determined at the point of maximal load and the energy stored in the samples for proportional stress--strain limit (elastic region). There were also no significant differences in the density of the samples.

The study shows that the enrichment of bisphosphonates causes yielding of the bone cement material. Due to the yielding, the elastic region of the material is not permanently destroyed when the same mechanical load is increased.

FTIR spectra of the bone cement and the bisphosphonate-enriched bone cement are shown in Fig. [4](#Fig4){ref-type="fig"}. Enrichment of bone cement with BP did not cause the appearance of additional peaks, indicative of the formation of new interaction (chemical bonds). A low-boost spectrum (slightly more intensive) at 808, 1,145, 1,193, 1,243, 1,452, 1,487, 1,523 wavelengths was observed. This indicates that the enrichment of bone cement with bisphosphonate in ratio of 40 g of bone cement to 60 mg of BP-enriched bone cement does not cause any visible changes in the chemical composite of bone cement. Fig. 4FTIR spectra of the bone cement and the BP-enriched cement

Discussion {#Sec8}
==========

The purpose of this study was to investigate the biomechanical effects of enriching bone cement with pamidronate. Some researchers showed that enrichment of bone cement with antibiotics changed some of its biomechanical properties \[[@CR18]\]. Others proved that even large amount of antibiotics implanted into bone cement did not adversely affect its mechanical properties \[[@CR19]\]. Therefore, bone cement with antibiotics is widely used. Enrichment of bone cement with BP allows the regulation of important mediators involved in osteoclastogenesis, such as RANKL synthesized by osteoblasts that modulates OPG, a decoy receptor of RANKL-absorbing and preventing RANK activation. In our earlier report, we proved that use of the bisphosphonate that was present in the bone cement had a positive effect on bone turnover by acting directly on some important markers in the rats' serum. Our next micro-CT study showed other beneficial effects on the bone's microarchitecture \[[@CR15]\]. Implanted BP-enriched bone cement simply changes the bone turnover in normal rats' bone toward a positive balance between bone formation and bone resorption. All those factors lead to a positive effect on bone formation together with enhanced growth.

In this paper, we used our own mathematical model for the calculations concerning the bone cement and the BP-enriched bone cement's response to load; however, we obtained results similar to those presented by Lewis in the analysis of mechanical properties of PMMA bone cement \[[@CR20]\]. We would also like to point out that there are major difficulties when comparing some of the results of the mechanical tests because of the variety of test conditions, sample preparation and methods of data analysis. However, we have to add that the stiffness of the bisphosphonate-enriched bone cement in the compressive test and Young's modulus was significantly decreased but only less than 5 %. Therefore, most important mechanical properties of BP-enriched cement were preserved \[[@CR20]\]. Other physical and mechanical properties such as density and maximal load were the same or even increased as in the case of strain. Implantation of pamidronate into the bone cement did not change chemical properties also.

Some researchers showed that the stress--strain limit of bone cement might be associated with prosthetic loosening \[[@CR21]\]. Yielding is a response to the plastic deformation of bone cement, but when it reaches levels over the yield stress level, it causes permanent deformation. Such deformation, also known as creep deformation, is undesirable in bone cement \[[@CR12]\]. In our experimental model, enrichment of bisphosphonates caused yielding of the bone cement material. It may even improve its efficiency during mechanical loading tests. However, it needs some further in vivo studies and analysis concerning fatigue potential of BP-enriched cement.

It is a well-known fact that bisphosphonates inhibit osteoclast-mediated bone resorption, play an important role in the healing of fractured bones, reduce osteoarthritis, prevent prosthetic migration or enhance bone allograft ingrowth \[[@CR22]--[@CR25]\]. Despite the fact that the effects of bisphosphonates on material-level properties of bone have been evaluated by many authors \[[@CR26]--[@CR28]\], the biomechanical properties of BP-enriched bone cement have not been investigated so far. In the presented data, we conclude that the implantation of pamidronate into bone cement did not aggravate its biomechanical properties. We believe that the local use of BP-enriched bone cement may be very efficient in the treatment of various bone diseases in humans, especially in those who require a positive balance between bone formation and bone resorption; therefore, the concept of using BP-enriched bone cement implants appears to be justified. We would like to add that BP-enriched bone cement has only been used in animal models thus far, but the results that we have obtained have encouraged us to perform additional in vivo experiments that assess the biomechanical properties of bones implanted with BP-enriched bone cement. Those experiments together with former research enable us to start new scientific programs which facilitate the potential use of BP-enriched bone cement and its further clinical application.
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